Recommendations for the medication of rheumatic diseases in periconceptional period
Zhang Wen, Li Yisha, Liu Dongzhou, Li Juan, Su Juan, Wang Li, Zhang Zhuoli, Zuo Xiaoxia, Zhao Yan, on behalf of Chinese Rheumatology Association
Abstract
Rheumatic diseases are a kind of chronic inflammatory diseases mainly involving joints and surrounding tissues. Most patients with rheumatic diseases need long-term treatment, which is difficult to be avoided during pregnancy. Treatment efficacy, as well as maternal and fetal safety should be taken into account in the medical decision. Based on the domestic and foreign guidelines, consensus, diagnosis and treatment experience, Chinese Rheumatology Association developed the standardization of medication use in patients with rheumatic diseases preparing and during pregnancy, aiming on the application and precautions of commonly used medicines for rheumatic diseases in preparing pregnancy, pregnancy and lactation.
Key words:
Rheumatic diseases; Periconceptional period; Treatment
Contributor Information
Zhang Wen
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &
Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 107300, China
Li Yisha
Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha 410008, China
Liu Dongzhou
Department of Rheumatology and Immunology, Shenzhen People′s Hospital, the Second Clinical Medical College, Jinan University, Shenzhen 518020, China
Li Juan
Department of Rheumatic &
TCM Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
Su Juan
Department of Rheumatology and Immunology, Qinghai University Affiliated Hospital, Xining 810001, China
Wang Li
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &
Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 107300, China
Zhang Zhuoli
Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China
Zuo Xiaoxia
Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha 410008, China
Zhao Yan
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &
Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 107300, China
on behalf of Chinese Rheumatology Association
